AU1769497A - Modified cytokines for therapeutic use - Google Patents

Modified cytokines for therapeutic use

Info

Publication number
AU1769497A
AU1769497A AU17694/97A AU1769497A AU1769497A AU 1769497 A AU1769497 A AU 1769497A AU 17694/97 A AU17694/97 A AU 17694/97A AU 1769497 A AU1769497 A AU 1769497A AU 1769497 A AU1769497 A AU 1769497A
Authority
AU
Australia
Prior art keywords
therapeutic use
modified cytokines
cytokines
modified
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17694/97A
Inventor
Giulia Casorati
Angelo Corti
Paolo Dellabona
Micaela Pelagi
Antonio Siccardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondazione Centro San Raffaele del Monte Tabor
Original Assignee
SAN RAFFAELE CENTRO FOND
Fondazione Centro San Raffaele del Monte Tabor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SAN RAFFAELE CENTRO FOND, Fondazione Centro San Raffaele del Monte Tabor filed Critical SAN RAFFAELE CENTRO FOND
Publication of AU1769497A publication Critical patent/AU1769497A/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU17694/97A 1996-02-27 1997-02-14 Modified cytokines for therapeutic use Abandoned AU1769497A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI96A0358 1996-02-27
IT96MI000358A IT1282692B1 (en) 1996-02-27 1996-02-27 CYTOKINES MODIFIED FOR THERAPY USE
PCT/EP1997/000704 WO1997031655A2 (en) 1996-02-27 1997-02-14 Modified cytokines for therapeutic use

Publications (1)

Publication Number Publication Date
AU1769497A true AU1769497A (en) 1997-09-16

Family

ID=11373397

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17694/97A Abandoned AU1769497A (en) 1996-02-27 1997-02-14 Modified cytokines for therapeutic use

Country Status (6)

Country Link
EP (1) EP0885015A2 (en)
JP (1) JP2000506835A (en)
AU (1) AU1769497A (en)
CA (1) CA2247308A1 (en)
IT (1) IT1282692B1 (en)
WO (1) WO1997031655A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012554A1 (en) * 1998-08-28 2000-03-09 Commissariat A L'energie Atomique Method for marked chemokine synthesis, marked chemokine and analysis kit
FR2783528A1 (en) * 1998-08-28 2000-03-24 Commissariat Energie Atomique Synthesis of labeled chemokine, useful for developing anti-inflammatory and antiviral agents uses conventional peptide synthesis with label attached to sidechain at predetermined position
DE19845798A1 (en) * 1998-09-29 2000-04-13 Schering Ag Use of neoangiogenesis markers for diagnosis and therapy of tumors, agents containing them, and methods for their production
AU2009207287B2 (en) * 2008-01-25 2014-09-11 Gavish-Galilee Bio Applications Ltd Targeting of innate immune response to tumor site
EA201892619A1 (en) * 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
AU2015231001A1 (en) 2014-03-21 2016-09-29 Abbvie Inc. Anti-EGFR antibodies and antibody drug conjugates
JP6751165B2 (en) 2016-06-08 2020-09-02 アッヴィ・インコーポレイテッド Anti-B7-H3 antibody and antibody drug conjugate
BR112018075649A2 (en) 2016-06-08 2019-04-09 Abbvie Inc. anti-b7-h3 antibodies and antibody drug conjugates
CA3027044A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
BR112018075630A2 (en) 2016-06-08 2019-03-19 Abbvie Inc. anti-cd98 antibodies and antibody drug conjugates
EP3612567B1 (en) 2017-04-19 2024-09-11 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
WO1995015979A1 (en) * 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds

Also Published As

Publication number Publication date
IT1282692B1 (en) 1998-03-31
ITMI960358A0 (en) 1996-02-27
CA2247308A1 (en) 1997-09-04
ITMI960358A1 (en) 1997-08-27
EP0885015A2 (en) 1998-12-23
WO1997031655A3 (en) 1997-11-13
WO1997031655A2 (en) 1997-09-04
JP2000506835A (en) 2000-06-06

Similar Documents

Publication Publication Date Title
AUPO203996A0 (en) Therapeutic uses
AU4787697A (en) Therapeutic gene
EP0796628A3 (en) Inhaler
AU3550197A (en) Syringes
AU2805195A (en) Therapeutic compounds
AU2654299A (en) Wheelchair
AU3539297A (en) Transdermal therapeutic systems
AU1769497A (en) Modified cytokines for therapeutic use
AU5141498A (en) Dilatation means
AUPO434196A0 (en) An improved therapeutic
AU6436998A (en) Therapeutic uses for antioxidants
GB9620777D0 (en) Therapeutic use
AU2547895A (en) Therapeutic phenoxyalkylheterocycles
AUPO118896A0 (en) New use
AU4582597A (en) Therapeutic proteins
AUPO440696A0 (en) New use
EP0904287A3 (en) Cytokine designated lerk-8
AU5330198A (en) Therapeutic compounds
AU7124098A (en) Adjustable bed
AU4956497A (en) Douche apparatus
AU6932396A (en) Easy-to-store coffin
ZA977005B (en) Therapeutic uses
AU1714195A (en) Therapeutic benzonitriles
AU3885995A (en) Novel medicinal use
AUPO314896A0 (en) Therapeutic agent